Absci Corporation (ABSI)
NASDAQ: ABSI · Real-Time Price · USD
3.580
-0.150 (-4.02%)
At close: Dec 5, 2025, 4:00 PM EST
3.561
-0.019 (-0.53%)
After-hours: Dec 5, 2025, 7:52 PM EST
Absci Revenue
Absci had revenue of $378.00K in the quarter ending September 30, 2025, a decrease of -77.78%. This brings the company's revenue in the last twelve months to $2.82M, down -33.09% year-over-year. In the year 2024, Absci had annual revenue of $4.53M, down -20.71%.
Revenue (ttm)
$2.82M
Revenue Growth
-33.09%
P/S Ratio
162.57
Revenue / Employee
$17,930
Employees
157
Market Cap
538.33M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ABSI News
- 1 day ago - Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia - GlobeNewsWire
- 1 day ago - 10 AI Stocks Worth Buying Right Now - The Motley Fool
- 14 days ago - Absci Corporation (ABSI) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 23 days ago - Absci Corporation (ABSI) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 5 weeks ago - Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025 - GlobeNewsWire
- 5 weeks ago - Absci to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial - GlobeNewsWire